MarketWatch

(PMZN) SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating ...

The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...

Truetide subsidiary Paraytec launches assay development programme

Truetide said on Wednesday that its wholly-owned subsidiary Paraytec had launched a focused development programme aimed at establishing a high-throughput, real-time fluorescent assay to study ...
ALZFORUM

Synuclein Assay Passes the Sniff Test—What of Other Seeds?

Seed amplification assays, those PCR-like reactions for toxic misfolded proteins, are starting to look pretty good. In the May Lancet Neurology, scientists led by Andrew Siderowf, University of ...
ALZFORUM

Not All Bad: Phosphorylated α-Synuclein Modulates Neurotransmission

Phosphorylation of α-synuclein at serine 129 has long been used as a marker of synucleinopathy—p-S129syn accumulates in Lewy bodies, after all. But does this modification have a physiological function ...
TMCnet

SynuSight Biotech, ABLi Therapeutics and XingImaging Announce Strategic Collaboration to Implement Alpha-Synuclein PET Imaging into Clinical Trials Evaluating Risvodetinib as a ...

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...